Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Emerging immunotherapies in older adults with acute myeloid leukemia.

Vasu S, Blum W.

Curr Opin Hematol. 2013 Mar;20(2):107-14. doi: 10.1097/MOH.0b013e32835d8101. Review.

2.

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhatia M, Bradley B, Del Toro G, George D, Garvin J, van de Ven C, Cairo MS.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7164s-7170s.

3.

Antigen-specific immunotherapies for acute myeloid leukemia.

Buckley SA, Walter RB.

Hematology Am Soc Hematol Educ Program. 2015;2015:584-95. doi: 10.1182/asheducation-2015.1.584. Review.

PMID:
26637776
4.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

5.

Update on antigen-specific immunotherapy of acute myeloid leukemia.

Buckley SA, Walter RB.

Curr Hematol Malig Rep. 2015 Jun;10(2):65-75. doi: 10.1007/s11899-015-0250-9. Review.

PMID:
25896530
6.

Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

Lekakis L, de Lima M.

Expert Rev Anticancer Ther. 2008 May;8(5):785-98. doi: 10.1586/14737140.8.5.785. Review.

PMID:
18471050
7.

What happened to anti-CD33 therapy for acute myeloid leukemia?

Jurcic JG.

Curr Hematol Malig Rep. 2012 Mar;7(1):65-73. doi: 10.1007/s11899-011-0103-0. Review.

PMID:
22109628
8.

Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.

Capelli D, Chiarucci M, Poloni A, Saraceni F, Mancini G, Trappolini S, Troiani E, Montanari M, Scortechini I, Offidani M, Rupoli S, Scortechini AR, Gini G, Discepoli G, Leoni P, Olivieri A.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1399-406. doi: 10.1016/j.bbmt.2014.05.019. Epub 2014 May 28.

9.

Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.

Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G.

Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894.

10.

A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.

Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9.

11.

Are immunoconjugates approaching "standard of care" in AML?

Estey E.

Best Pract Res Clin Haematol. 2013 Sep;26(3):261-8. doi: 10.1016/j.beha.2013.10.006. Epub 2013 Oct 16. Review.

PMID:
24309528
12.

Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.

Tettamanti S, Magnani CF, Biondi A, Biagi E.

Immunol Lett. 2013 Sep-Oct;155(1-2):43-6. doi: 10.1016/j.imlet.2013.09.013. Epub 2013 Sep 25. Review.

PMID:
24076117
13.

Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?

Finn LE, Foran JM.

Curr Opin Hematol. 2016 Mar;23(2):95-101. doi: 10.1097/MOH.0000000000000220. Review.

PMID:
26825695
14.

Acute myeloid leukemia.

Stone RM, O'Donnell MR, Sekeres MA.

Hematology Am Soc Hematol Educ Program. 2004:98-117. Review.

PMID:
15561679
15.

Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.

Jackson K, Kennedy G, Mollee P, Marlton P, Morris K.

Asia Pac J Clin Oncol. 2014 Sep;10(3):246-54. doi: 10.1111/ajco.12188. Epub 2014 Mar 27.

PMID:
24673966
16.

Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns.

Gupta V, Tallman MS, Weisdorf DJ.

Blood. 2011 Feb 24;117(8):2307-18. doi: 10.1182/blood-2010-10-265603. Epub 2010 Nov 22. Review. Erratum in: Blood. 2012 Dec 20;120(26):5250.

17.

Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.

Eom KS, Kim HJ, Cho BS, Choi SM, Lee DG, Lee SE, Yahng SA, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Park CW, Min WS.

Leuk Lymphoma. 2011 Dec;52(12):2321-8. doi: 10.3109/10428194.2011.587562. Epub 2011 Oct 24.

PMID:
22023488
18.

Current and emerging therapies for acute myeloid leukemia.

Robak T, Wierzbowska A.

Clin Ther. 2009;31 Pt 2:2349-70. doi: 10.1016/j.clinthera.2009.11.017. Review.

PMID:
20110045
19.

[Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia--recent progress].

Okamoto S.

Nihon Rinsho. 2009 Oct;67(10):1944-50. Review. Japanese.

PMID:
19860195
20.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

Supplemental Content

Support Center